These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 10146973)

  • 1. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.
    Fitton A; Benfield P
    Pharmacoeconomics; 1993 Aug; 4(2):131-56. PubMed ID: 10146973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Medical economic impact of schizophrenia].
    Martin P
    Encephale; 1995 Jun; 21 Spec No 3():67-73. PubMed ID: 7628346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.
    Fitton A; Heel RC
    Drugs; 1990 Nov; 40(5):722-47. PubMed ID: 2292234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
    Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
    Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
    N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies.
    Revicki DA
    J Clin Psychiatry; 1999; 60 Suppl 1():7-11; discussion 28-30. PubMed ID: 10037164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.
    Meltzer HY; Cola P; Way L; Thompson PA; Bastani B; Davies MA; Snitz B
    Am J Psychiatry; 1993 Nov; 150(11):1630-8. PubMed ID: 8105705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
    Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
    Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
    Essock SM; Frisman LK; Covell NH; Hargreaves WA
    Arch Gen Psychiatry; 2000 Oct; 57(10):987-94. PubMed ID: 11015817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.
    Davies LM; Drummond MF
    Br J Psychiatry; 1993 Jan; 162():38-42. PubMed ID: 8425137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
    Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Allan E; Erdos J; Frisman LK; Xu W; Thomas J; Henderson W; Charney D
    Arch Gen Psychiatry; 1999 Jun; 56(6):565-72. PubMed ID: 10359474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system.
    Reid WH; Mason M
    J Clin Psychiatry; 1998 Apr; 59(4):189-94. PubMed ID: 9590670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine: current status and role in the pharmacotherapy of schizophrenia.
    Remington GJ; Addington D; Collins EJ; Jones BD; Lalonde P; MacCrimmon DJ; MacEwan GW
    Can J Psychiatry; 1996 Apr; 41(3):161-6. PubMed ID: 8722645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacoeconomics of clozapine: a review.
    Meltzer HY; Cola PA
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():161-5. PubMed ID: 7961564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Business Case for Expanded Clozapine Utilization.
    Gören JL; Rose AJ; Smith EG; Ney JP
    Psychiatr Serv; 2016 Nov; 67(11):1197-1205. PubMed ID: 27301766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.